EM-9017
| EM-9017
|
|---|
EM-9017 is a novel pharmaceutical compound currently under investigation for its potential therapeutic applications in the treatment of chronic pain and neuropathic disorders. This article provides a comprehensive overview of EM-9017, including its chemical properties, mechanism of action, clinical trials, and potential side effects.
Chemical Properties[edit]
EM-9017 is a synthetic compound with a complex molecular structure. It is classified as a small molecule drug, designed to interact with specific receptors in the central nervous system. The chemical formula of EM-9017 is C20H25N3O3, and it has a molecular weight of 355.44 g/mol.
Mechanism of Action[edit]
EM-9017 functions primarily as a selective agonist for the GABAB receptor, a type of G-protein coupled receptor that plays a crucial role in modulating neurotransmission in the brain. By activating these receptors, EM-9017 enhances inhibitory neurotransmission, which can lead to a reduction in neuronal excitability and a decrease in the perception of pain.
Clinical Trials[edit]
EM-9017 is currently undergoing Phase II clinical trials to evaluate its efficacy and safety in patients with chronic pain conditions, such as fibromyalgia and diabetic neuropathy. Preliminary results have shown promise, with many participants reporting significant pain relief and improved quality of life.
Potential Side Effects[edit]
As with any pharmacological agent, EM-9017 may cause side effects. Commonly reported adverse effects include dizziness, fatigue, and nausea. More serious side effects, although rare, may include respiratory depression and hypotension. Ongoing studies aim to further elucidate the safety profile of EM-9017.
Regulatory Status[edit]
EM-9017 has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The drug is currently available only for research purposes and is not yet marketed for clinical use.
Also see[edit]
| Pharmacology | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology
| Major chemical drug groups | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian